Resumen
This invention relates to the use of an inductor or activator compound GSE24.2 for producing a medicament or a pharmaceutical composition for treating a preferably human illness or pathological situation caused by a senescence process. Said pharmaceutical composition can be useful for a treatment for regenerating tissues, for example of epithelial tissues or haematopoietic cells, and also for the immortalisation of eucaryotic cells in order to use of same in biotechnological investigation or processes.
Reivindicaciones
1. Use of an inductor or activator compound GSE24.2 for producing a medicament or pharmaceutical composition for treating a preferably human illness or pathological situation, caused by a process of altered senescence. 2. Use of a compound according to claim 1 characterised in that the illness is due to a natural process of senescence as a result of natural ageing. 3. Use of a compound according to claim 1 characterised in that the illness is due to a pathological process of accelerated senescence. 4. Use of a compound according to claim 2 characterised in that the natural senescence process affects epithelial tissue or a tissue with a high level of proliferation. 5. Use of a compound according to claim 4 characterised in that the epithelial tissue belongs to the following group: skin, preferably, of the epidermis, gut, cornea, liver, lung and hair bulb. 6. Use of a compound according to claim 4 characterised in that the tissue with a high level of proliferation belongs to the following group: cells of the haematopoietic system, preferably lymphocytes, macrophages and erythrocytes; germinal cells. 7. Use of a compound according to claim 4 to 6 characterised in that the cells are somatic cells, trunk cells or embryonic cells. 8. Use of a compound according to claim 1 characterised in that the inductor agent GSE24.2 is a sequence of nucleotides that allows the expression of a protein or peptide that induces recovery from senescence inside the cells of a mammal, preferably human, and that is composed of one or several sequences of nucleotides GSE 24.2 belonging to the following group: a) a sequence of nucleotides composed of a human GSE 24.2 nucleotides sequence (SEQ ID NO1), b) a variant of the nucleotide sequence of a) that shows an identity in the sequence of nucleotides of at least 90% with SEQ ID NO1, c) a fragment of any of the sequences of a) and b), and d) a sequence of nucleotides, genetic construction, which comprises any sequence of a), b) and c). 9. Use of a compound according to claim 8 characterised in that the sequence of nucleotides is a sequence of DNA, cDNA or mRNA. 10. Use of a compound according to claim 8 characterised in that the sequence of nucleotides of sequence GSE 24.2 of a) is composed of SEQ ID NO1. 11. Use of a compound according to claim 8 characterised in that the sequence of nucleotides of sequence GSE 24.2 of c) is composed of SEQ ID NO3 or SEQ ID NO5, which encode peptide domains Trub I and Trub II, respectively. 12. Use of a compound according to claim 8 characterised in that the sequence of nucleotides is a genetic construction GSE 24.2 which comprises sequence GSE24.2. 13. Use of a compound according to claim 8 characterised in that the sequence of nucleotides is an expression vector GSE 24.2 comprising a sequence of nucleotides GSE 24.2 or a genetic construction GSE 24.2 and allows the expression of a protein or peptide capable of diminishing or reversing the process of senescence. 14. Use of a compound according to claim 13 characterised in that the expression vector is the plasmid pLNCX 24.2. 15. Use of a compound according to claim 1 characterised in that the inductor agent GSE24.2 is a protein or peptide presenting senescence reversal activity inside the cells of a mammal, preferably human, and comprising one or several sequences of amino acids belonging to the following group: a) a sequence of amino acids composed of a sequence of human GSE 24.2 amino acids (SEQ ID NO2), b) a variant sequence of amino acids according to the sequence of a) which shows an identity in the amino acid sequence of at least 90% with the polypeptide of SEQ ID NO2, c) a fragment of any of the sequences of a) and b), and d) a sequence of amino acids that comprises any sequence belonging to a), b) and c). 16. Use of a compound according to claim 15 characterised in that the inductor agent GSE24.2 is a protein whose sequence of amino acids of a) is composed of SEQ ID NO2. 17. Use of a compound according to claim 15 characterised in that the inductor agent GSE24.2 is a protein whose sequence of amino acids of c) is composed of SEQ ID NO4 or SEQ ID NO6. 18. Use of a compound according to claim 1 characterised in that inductor agent GSE24.2 is a eukaryote cell, preferably a human cell, transformed by means of these nucleotide sequences GSE 24.2, of different cell lineages, which can be used as regenerator cells of human tissues. 19. Pharmaceutical composition or medicament for treating an illness or pathology related to alterations of senescence characterised in that it comprises a compound or activator compound GSE 24.2, in a therapeutically effective quantity together with, optionally, one or more adjuvants and/or pharmaceutically acceptable vehicles and that is capable of diminishing or reversing the process of senescence, and obtained by means of the use of the invention and obtained according to the use of a compound according to claims 1 to 18. 20. Use of the pharmaceutical composition according to claim 19 in a procedure of treating an illness or pathological situation caused by a process of altered senescence affecting human beings. 21. Use of the pharmaceutical composition according to claim 19 in a procedure of immortalising eukaryote cells, preferably human or of animals used in biomedical research. 22. Eukaryote cell, preferably a human cell, characterised in that it presents a reversed or diminished process of senescence and in that it comprises the element GSE24.2.
